Figure 1 | Scientific Reports

Figure 1

From: Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis

Figure 1The alternative text for this image may have been generated using AI.

Inducing a primary immune response against an oncolytic virus-encoded transgene made the virus safer. (a) To assess the impact of primary vaccination on the safety of an oncolytic virus, when administered as a booster vaccine, tumor-free mice received intramuscular injections of 1 × 108 IU of an E1/E3-deleted replication-deficient human serotype 5 adenovirus (Ad) with a transgene encoding an antigen on day −14. This was followed fourteen days later (on study day 0) by intravenous administration of 3 × 109 pfu of vesicular stomatitis virus (VSV) encoding the same antigen. Survival was measured in days following treatment with VSV. Controls received an Ad that lacked a transgene but the same VSV-vectored vaccine as the test mice. Kaplan–Meier survival plots were calculated for (b) C57BL/6 or (c) Balb/c mice that were primed with Ad expressing (b) the immunodominant epitope from ovalbumin (OVA257-264) or (c) full-length human dopachrome tautomerase (hDCT) followed fourteen days later by intravenous boosting with VSV encoding the same antigen. Controls received adenoviruses that lacked a transgene (Ad-BHG). Mice were monitored and euthanized if they showed signs of reaching endpoint, which was always the onset of hind-limb weakness or paralysis. The data were analyzed using the Mantel-Cox log-rank method. Out of consideration for animal welfare, data shown in (b,c) were derived from single experiments.

Back to article page